Achyut Healthcare Limited, originally incorporated as Achyut Securities Private Limited in 1996, transitioned to its current name and public status in 2021. The company specializes in trading a diverse range of pharmaceutical products such as Cenzure, Tacrolimus USP, and Favipiravir. Since entering the pharmaceutical trading sector in 2015, it has built a strong domestic and international presence, serving markets in India, UAE, Kenya, and Nigeria, among others.
Achyut Healthcare's strategic operations are backed by a professional team managing procurement, marketing, and distribution, leveraging multi-location facilities to enhance market penetration. The company raised Rs. 3.6 crore through an IPO in March 2022, reflecting its growth and expansion ambitions. With a focus on high-quality, customized solutions, Achyut Healthcare continues to cater to a wide array of clients including end users, merchants, distributors, and exporters, maintaining a robust pan-India and global market presence.
